What is iBio's operating income?

iBio's total operating income in 2025 was -$18.60 million, based on the following breakdown: Total Gross Profit: $400 thousand Total Operating Expenses: $19.00 million

iBio (IBIO) Financials

$1.35 -0.08 (-5.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 +0.00 (+0.37%)

As of 07:20 PM Eastern

Compare

Annual Income Statements for iBio

This table shows iBio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Net Income / (Loss) Attributable to Common Shareholders	-6.63	-9.76	-15	-16	-18	-55	-23	-50	-65	-25	-18
Consolidated Net Income / (Loss)	-6.63	-11	-16	-16	-18	-16	-23	-50	-65	-25	-18
Net Income / (Loss) Continuing Operations	-6.63	-11	-16	-16	-18	-16	-23	-30	-29	-15	-18
Total Pre-Tax Income	-6.63	-11	-16	-16	-18	-16	-23	-30	-29	-15	-18
Total Operating Income	-6.67	-9.89	-14	-14	-16	-14	-31	-30	-29	-17	-19
Total Gross Profit	1.85	0.95	0.39	0.44	2.02	0.94	0.91	1.88	0.00	0.23	0.40
Total Revenue	1.85	0.95	0.39	0.44	2.02	1.64	2.37	1.88	0.00	0.23	0.40
Operating Revenue	1.85	0.95	0.39	0.44	2.02	1.64	2.37	1.88	0.00	0.23	0.40
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.70	1.46	0.00	0.00	0.00	0.00
Total Operating Expenses	8.52	11	15	15	18	15	32	32	29	17	19
Selling, General & Admin Expense	5.02	7.69	11	11	12	11	22	22	19	12	11
Research & Development Expense	3.50	3.16	4.12	3.99	5.47	3.57	9.99	9.83	10	5.19	8.31
Total Other Income / (Expense), net	0.04	-0.76	-1.87	-1.88	-1.81	-2.44	7.90	0.18	0.13	1.19	0.23
Interest Expense	0.00	0.81	1.93	1.92	1.90	2.47	2.45	0.00	0.08	0.17	0.21
Interest & Investment Income	0.04	0.04	0.06	0.03	0.09	0.03	0.15	0.18	0.21	0.36	0.44
Other Income / (Expense), net	-	-	-	-	-	0.00	10	0.00	0.00	1.00	0.00
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	-	-21	-36	-9.46	0.00
Basic Earnings per Share	($0.09)	($0.12)	($1.64)	($1.54)	($0.94)	($0.61)	($3.00)	($5.78)	($106.19)	($6.50)	($1.75)
Weighted Average Basic Shares Outstanding	71.50M	80.97M	8.91M	10.63M	18.93M	62.80M	7.83M	8.72M	612K	3.83M	10.50M
Diluted Earnings per Share	($0.09)	($0.12)	($1.64)	($1.54)	($0.94)	($0.61)	($3.00)	($5.78)	($106.19)	($6.50)	($1.75)
Weighted Average Diluted Shares Outstanding	71.50M	80.97M	8.91M	10.63M	18.93M	62.80M	7.83M	8.72M	612K	3.83M	10.50M
Weighted Average Basic & Diluted Shares Outstanding	71.50M	80.97M	8.91M	10.63M	18.93M	62.80M	195.62M	-	27.59M	8.64M	19.65M

This table shows iBio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-5.75	-8.21	-3.17	-7.78	-3.99	-4.36	-4.86	-5.16	-5.72	-8.99	-7.73
Consolidated Net Income / (Loss)	-5.75	-8.21	-3.17	-7.78	-3.99	-4.36	-4.86	-5.16	-5.72	-8.99	-7.73
Net Income / (Loss) Continuing Operations	-5.07	-4.49	-2.64	-3.25	-3.99	-4.36	-4.86	-5.16	-5.72	-8.99	-7.73
Total Pre-Tax Income	-5.07	-4.49	-2.64	-3.25	-3.99	-4.36	-4.86	-5.16	-5.72	-8.99	-7.73
Total Operating Income	-5.10	-4.50	-3.63	-3.41	-4.11	-4.42	-4.88	-5.20	-5.95	-9.45	-8.37
Total Gross Profit	0.05	0.00	0.00	0.18	0.00	0.20	0.00	0.20	0.10	0.00	0.00
Total Revenue	0.05	0.00	0.00	0.18	0.00	0.20	0.00	0.20	0.10	0.00	0.00
Operating Revenue	0.05	0.00	0.00	0.18	0.00	0.20	0.00	0.20	0.10	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00
Total Operating Expenses	5.15	4.50	3.63	3.58	4.11	4.62	4.88	5.40	6.05	9.45	8.37
Selling, General & Admin Expense	3.55	2.96	2.72	2.44	2.80	2.74	2.97	2.17	2.50	5.17	5.11
Research & Development Expense	1.61	1.54	0.90	1.14	1.31	1.88	1.91	3.22	3.55	4.28	3.25
Total Other Income / (Expense), net	0.03	0.01	0.99	0.16	0.12	0.06	0.02	0.04	0.23	0.45	0.64
Interest Expense	0.03	0.03	0.05	0.06	0.06	0.06	0.05	0.04	0.04	0.04	0.02
Interest & Investment Income	0.06	0.04	0.04	0.22	0.17	0.11	0.07	0.08	0.27	0.49	0.66
Basic Earnings per Share	($4.80)	($4.42)	($0.85)	($2.03)	($0.46)	($0.48)	($0.49)	($0.49)	($0.11)	($0.09)	($0.06)
Weighted Average Basic Shares Outstanding	1.20M	1.86M	3.71M	3.83M	8.63M	9.13M	9.86M	10.50M	52.98M	99.13M	119.60M
Diluted Earnings per Share	($4.80)	($4.42)	($0.85)	($2.03)	($0.46)	($0.48)	($0.49)	($0.49)	($0.11)	($0.09)	($0.06)
Weighted Average Diluted Shares Outstanding	1.20M	1.86M	3.71M	3.83M	8.63M	9.13M	9.86M	10.50M	52.98M	99.13M	119.60M
Weighted Average Basic & Diluted Shares Outstanding	28.10M	3.48M	8.62M	8.64M	9.15M	9.87M	16.52M	19.65M	22.49M	34.54M	49.68M

This table details how cash moves in and out of iBio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Net Change in Cash & Equivalents	5.90	14	-15	7.85	-12	51	22	-49	-21	6.85	-5.63
Net Cash From Operating Activities	-4.73	-8.07	-13	-13	-14	-13	-30	-37	-30	-19	-15
Net Cash From Continuing Operating Activities	-4.73	-8.07	-13	-13	-14	-13	-30	-37	-30	-19	-15
Net Income / (Loss) Continuing Operations	-6.63	-11	-16	-16	-18	-16	-23	-50	-65	-25	-18
Consolidated Net Income / (Loss)	-6.63	-11	-16	-16	-18	-16	-23	-50	-65	-25	-18
Depreciation Expense	0.01	0.58	1.33	1.37	1.43	0.28	0.47	2.28	0.67	0.64	0.48
Amortization Expense	0.36	0.36	0.35	0.34	0.32	1.96	0.51	1.94	0.44	0.73	0.64
Non-Cash Adjustments To Reconcile Net Income	0.96	1.25	1.01	0.83	0.42	0.39	3.32	10	28	7.85	1.34
Changes in Operating Assets and Liabilities, net	0.58	0.40	0.29	0.09	1.45	0.47	-11	-1.84	5.92	-2.87	0.60
Net Cash From Investing Activities	-0.22	-0.07	-1.59	-1.08	-0.99	-1.15	-26	-5.13	7.01	0.91	0.74
Net Cash From Continuing Investing Activities	-0.22	-0.07	-1.59	-1.08	-0.99	-1.15	-26	-5.13	7.01	0.91	0.74
Purchase of Property, Plant & Equipment	-0.01	-0.07	-1.32	-0.93	-0.92	-1.08	-4.92	-7.33	-5.74	-0.21	-0.02
Sale of Property, Plant & Equipment	-	-	-	-	-	-	-	0.00	2.60	0.12	0.00
Divestitures	-	-	-	-	-	-	-	-	0.00	1.00	0.00
Other Investing Activities, net	-	-	-	-	-	0.00	-1.50	-1.76	-	0.00	0.76
Net Cash From Financing Activities	11	22	-0.17	22	3.45	65	79	-6.13	2.30	24	8.93
Net Cash From Continuing Financing Activities	11	22	-0.17	22	3.45	65	79	-6.13	2.30	24	8.93
Repayment of Debt	0.00	-0.57	-0.17	-0.18	-0.20	-2.00	-	0.00	-9.44	-0.87	5.85
Issuance of Debt	-	-	-	-	0.00	-	-	-	0.50	0.20	0.00
Issuance of Common Equity	10	21	0.00	23	1.35	62	78	0.00	11	26	3.54
Other Financing Activities, net	0.87	1.01	0.00	1.09	2.46	6.99	5.27	-6.08	-0.21	-0.37	-0.46
Cash Interest Paid	0.00	0.49	1.93	1.92	1.90	2.37	2.45	1.05	0.69	0.75	0.21

This table details how cash moves in and out of iBio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-2.82	-0.70	2.37	7.99	-3.16	-4.02	-2.06	3.61	20	0.56	19
Net Cash From Operating Activities	-5.34	-4.71	-3.65	-4.85	-3.72	-3.87	-3.11	-4.62	-5.67	-5.24	-6.08
Net Cash From Continuing Operating Activities	-5.34	-4.71	-3.65	-4.85	-3.72	-3.87	-3.11	-4.62	-5.67	-5.24	-6.08
Net Income / (Loss) Continuing Operations	-5.75	-8.21	-3.17	-7.78	-3.99	-4.36	-4.86	-5.16	-5.72	-8.99	-7.73
Consolidated Net Income / (Loss)	-5.75	-8.21	-3.17	-7.78	-3.99	-4.36	-4.86	-5.16	-5.72	-8.99	-7.73
Depreciation Expense	0.17	0.16	0.16	0.15	0.12	0.12	0.12	0.12	0.12	0.14	0.15
Amortization Expense	0.24	0.19	0.17	0.14	0.16	-0.15	0.47	0.16	-0.00	-0.07	0.29
Non-Cash Adjustments To Reconcile Net Income	0.62	3.20	-0.61	4.65	0.31	0.67	0.35	0.01	0.37	2.79	2.17
Changes in Operating Assets and Liabilities, net	-0.62	-0.04	-0.20	-2.00	-0.32	-0.15	0.81	0.26	-0.43	0.89	-0.96
Net Cash From Investing Activities	0.05	-	1.00	-0.14	0.71	-0.00	-0.01	0.05	-21	-2.98	-3.11
Net Cash From Continuing Investing Activities	0.05	-	1.00	-0.14	0.71	-0.00	-0.01	0.05	-21	-2.98	-3.11
Purchase of Property, Plant & Equipment	0.05	-0.05	-	-0.21	0.00	-0.00	-0.01	-0.00	-0.03	-0.52	-0.01
Purchase of Investments	-	-	-	-	0.00	-	-	-	-21	-2.47	-8.50
Net Cash From Financing Activities	2.47	4.01	5.03	13	-0.16	-0.15	1.06	8.18	47	8.79	28
Net Cash From Continuing Financing Activities	2.47	4.02	5.03	13	-0.16	-0.15	1.06	8.18	47	8.79	28
Repurchase of Common Equity	-	-	-	-	-	-	-	-	-	-	-2.05
Issuance of Common Equity	2.81	4.12	4.28	14	0.00	-	1.13	2.41	0.22	56	34
Other Financing Activities, net	-0.07	-0.07	-0.07	-0.17	-0.07	-0.06	0.04	-0.37	-3.52	7.22	-3.65

This table presents iBio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Total Assets	12	52	36	43	31	94	147	99	41	29	23
Total Current Assets	10	24	8.57	16	4.81	62	105	45	26	16	9.72
Cash & Equivalents	9.49	23	8.09	16	4.42	55	77	23	4.30	14	8.58
Short-Term Investments	-	-	-	-	-	-	20	11	-	-	0.00
Accounts Receivable	0.45	0.61	0.18	0.08	0.10	0.08	0.43	1.00	0.20	0.00	0.00
Prepaid Expenses	0.18	0.26	0.28	0.28	0.29	0.21	2.07	1.55	0.66	0.75	1.03
Other Current Assets	-	-	-	-	0.00	5.55	5.10	9.00	18	-	0.11
Plant, Property, & Equipment, net	0.01	26	26	25	24	3.66	8.63	1.37	4.22	3.63	3.16
Total Noncurrent Assets	2.36	2.12	1.85	1.65	1.40	29	34	53	11	9.43	10
Noncurrent Note & Lease Receivables	-	-	-	-	0.00	28	28	1.63	2.32	1.42	1.17
Intangible Assets	2.36	2.09	1.82	1.62	1.37	1.14	0.95	4.85	5.39	5.37	6.85
Other Noncurrent Operating Assets	0.00	0.03	0.03	0.03	0.02	0.02	5.12	9.17	3.03	2.64	2.29
Total Liabilities & Shareholders' Equity	12	52	36	43	31	94	147	99	41	29	23
Total Liabilities	1.26	28	27	27	28	38	38	36	26	7.41	8.31
Total Current Liabilities	1.26	2.29	2.01	2.04	3.46	5.24	6.65	30	22	3.84	6.11
Short-Term Debt	0.00	0.17	0.18	0.20	0.21	0.26	0.60	22	13	0.52	0.83
Accounts Payable	1.10	1.18	0.75	0.79	1.00	1.76	2.25	4.26	1.85	0.36	2.19
Accrued Expenses	0.16	0.92	0.92	1.05	0.97	1.11	3.00	3.76	4.56	2.03	1.35
Other Current Liabilities	-	-	-	0.00	1.28	0.30	0.37	0.09	2.60	0.74	1.74
Total Noncurrent Liabilities	0.00	25	25	25	25	32	32	5.49	3.72	3.57	2.20
Other Noncurrent Operating Liabilities	-	-	-	-	0.00	-	0.00	3.51	3.13	2.69	2.20
Total Equity & Noncontrolling Interests	11	24	8.92	16	2.46	57	109	63	15	21	15
Total Preferred & Common Equity	11	9.94	8.91	16	2.46	57	109	63	15	21	15
Preferred Stock	0.00	0.00	-	-	0.00	-	0.00	0.00	0.00	-	0.00
Total Common Equity	11	9.94	8.91	16	2.46	57	109	63	15	21	15
Common Stock	59	68	81	104	108	207	282	288	304	335	347
Retained Earnings	-48	-58	-72	-88	-106	-150	-174	-224	-289	-314	-332
Accumulated Other Comprehensive Income / (Loss)	-0.03	-0.03	-0.03	-0.03	-0.03	-0.03	-0.06	-0.21	-	-	0.00

This table presents iBio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	9/30/2024	12/31/2024	3/31/2025	9/30/2025	12/31/2025	3/31/2026
Total Assets	38	34	50	25	22	19	64	64	86
Total Current Assets	23	20	36	12	8.29	6.06	51	53	77
Cash & Equivalents	1.46	2.79	5.30	11	7.02	4.96	28	29	48
Short-Term Investments	-	-	-	-	-	-	21	24	27
Accounts Receivable	-	-	-	-	0.01	-	0.07	0.00	0.00
Prepaid Expenses	0.45	0.89	0.86	0.67	1.26	1.10	1.14	0.67	2.45
Other Current Assets	18	15	29	-	-	-	0.00	0.00	0.00
Plant, Property, & Equipment, net	4.05	3.89	3.73	3.51	3.39	3.28	3.21	3.45	3.31
Total Noncurrent Assets	11	10	10	9.30	10	9.76	10	7.58	5.27
Noncurrent Note & Lease Receivables	2.27	2.23	2.18	1.37	1.32	1.27	1.12	1.14	1.16
Intangible Assets	5.38	5.38	5.37	5.36	6.11	6.10	6.84	4.34	1.83
Other Noncurrent Operating Assets	2.95	2.83	2.74	2.57	2.60	2.39	2.21	2.10	2.29
Total Liabilities & Shareholders' Equity	38	34	50	25	22	19	64	64	86
Total Liabilities	24	25	25	6.76	7.80	7.72	8.12	7.83	8.30
Total Current Liabilities	21	22	21	3.47	4.71	5.40	6.05	5.90	6.50
Short-Term Debt	13	13	13	0.41	0.99	1.39	0.72	0.00	0.00
Accounts Payable	1.91	1.86	1.23	0.86	0.61	1.48	2.82	2.65	3.04
Accrued Expenses	3.39	3.76	4.00	1.08	1.84	1.33	0.85	1.58	1.79
Other Current Liabilities	0.84	1.35	1.40	0.73	0.67	0.61	1.65	1.67	1.68
Total Noncurrent Liabilities	3.76	3.27	3.87	3.29	3.09	2.33	2.07	1.93	1.79
Other Noncurrent Operating Liabilities	0.46	0.16	0.93	2.57	2.45	2.33	2.07	1.93	1.79
Total Equity & Noncontrolling Interests	13	9.20	25	18	14	11	56	57	78
Total Preferred & Common Equity	13	9.20	25	18	14	11	56	57	78
Preferred Stock	0.00	0.00	0.00	-	-	-	-	0.00	0.00
Total Common Equity	13	9.20	25	18	14	11	56	57	78
Common Stock	308	312	331	336	336	338	394	403	432
Retained Earnings	-295	-303	-306	-318	-322	-327	-338	-347	-355
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-	-	-0.02	0.01	-0.02

This table displays calculated financial ratios and metrics derived from iBio's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
DEI Shares Outstanding	76,755,410.00	89,109,410.00	89,118,510.00	115,918,510.00	19,702,458.00	118,360,032.00	217,850,344.00	218,165,624.00	16,798,014.00	8,623,676.00	16,519,281.00
DEI Adjusted Shares Outstanding	15,351.00	17,822.00	17,824.00	23,184.00	39,405.00	236,720.00	435,701.00	436,331.00	839,901.00	8,623,676.00	16,519,281.00
DEI Earnings Per Adjusted Shares Outstanding	-431.57	-547.86	-820.35	-705.87	-453.06	-231.07	-53.86	-115.49	-77.40	-2.89	-1.11
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	802.93%	-48.78%	-58.44%	12.69%	354.50%	-18.83%	44.75%	-20.54%	-100.00%	0.00%	77.78%
EBITDA Growth	-81.28%	-42.04%	-40.71%	0.64%	-12.15%	16.22%	-69.46%	-27.87%	-10.78%	49.48%	-22.52%
EBIT Growth	-73.68%	-48.41%	-44.28%	0.33%	-10.97%	11.31%	-49.33%	-42.02%	1.19%	46.72%	-18.98%
NOPAT Growth	-73.59%	-48.41%	-44.28%	0.33%	-10.97%	11.31%	-122.17%	4.55%	1.19%	43.31%	-11.83%
Net Income Growth	-80.71%	-60.86%	-51.44%	0.19%	-9.24%	6.55%	-41.16%	-116.71%	-29.23%	61.69%	26.22%
EPS Growth	-50.00%	-33.33%	-51.44%	6.10%	38.96%	35.11%	-41.16%	-116.71%	-29.23%	93.88%	73.08%
Operating Cash Flow Growth	-14.80%	-70.84%	-63.07%	-2.41%	-3.67%	4.51%	-125.28%	-24.67%	18.79%	39.04%	17.52%
Free Cash Flow Firm Growth	14.28%	-712.83%	69.61%	4.58%	5.64%	-142.29%	-50.71%	119.99%	-502.43%	106.23%	-833.94%
Invested Capital Growth	-30.77%	1,423.60%	-1.41%	-2.99%	-9.45%	48.79%	28.88%	-61.69%	29.14%	-60.84%	-16.29%
Revenue Q/Q Growth	6.38%	-4.15%	-24.52%	-11.20%	53.58%	24.75%	-20.97%	-20.67%	0.00%	350.00%	6.67%
EBITDA Q/Q Growth	-13.40%	-6.53%	-9.41%	-0.64%	-0.71%	9.58%	16.88%	-1.11%	13.11%	17.52%	-11.38%
EBIT Q/Q Growth	-12.60%	-9.50%	-8.39%	-0.62%	-0.68%	7.43%	17.09%	-3.54%	15.76%	14.05%	-10.64%
NOPAT Q/Q Growth	-12.60%	-9.50%	-8.39%	-0.62%	-0.68%	7.43%	-26.46%	-3.54%	15.76%	8.55%	-10.64%
Net Income Q/Q Growth	-12.65%	-14.33%	-7.38%	-0.55%	-0.49%	5.54%	13.60%	-51.81%	14.50%	-7.53%	12.46%
EPS Q/Q Growth	-12.50%	-9.09%	-7.38%	-9.22%	-2.17%	-24.49%	13.60%	-51.81%	14.50%	-4.17%	17.84%
Operating Cash Flow Q/Q Growth	-12.45%	-25.01%	-7.72%	2.81%	-7.85%	3.79%	-12.58%	-12.88%	17.67%	0.62%	1.54%
Free Cash Flow Firm Q/Q Growth	-8.53%	-3.07%	-12.43%	7.72%	22.38%	-203.05%	42.90%	116.66%	-22,084.92%	107.14%	-169.28%
Invested Capital Q/Q Growth	-17.76%	-0.12%	0.99%	-2.21%	-12.06%	797.81%	32.09%	-67.09%	-19.15%	-76.59%	-8.74%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	57.08%	38.34%	100.00%	0.00%	100.00%	100.00%
EBITDA Margin	-340.52%	-944.41%	-3,197.46%	-2,819.37%	-695.69%	-718.07%	-840.66%	-1,352.81%	0.00%	-6,339.56%	-4,369.00%
Operating Margin	-360.13%	-1,043.57%	-3,622.84%	-3,204.28%	-782.36%	-854.88%	-1,312.15%	-1,576.27%	0.00%	-7,392.89%	-4,650.50%
EBIT Margin	-360.13%	-1,043.57%	-3,622.84%	-3,204.28%	-782.36%	-854.88%	-881.95%	-1,576.27%	0.00%	-6,948.44%	-4,650.50%
Profit (Net Income) Margin	-357.91%	-1,124.16%	-4,096.19%	-3,627.93%	-872.00%	-1,003.91%	-979.04%	-2,670.06%	0.00%	-11,069.78%	-4,594.25%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	170.45%	222.54%	161.28%	100.00%
Interest Burden Percent	99.38%	107.72%	113.07%	113.22%	111.46%	117.43%	111.01%	99.38%	99.56%	98.78%	98.79%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-219.79%	-49.11%	-38.02%	-38.75%	-45.83%	-34.38%	-55.80%	-68.40%	0.00%	-76.96%	-166.48%
ROIC Less NNEP Spread (ROIC-NNEP)	-189.85%	56.41%	-100.76%	-85.47%	-90.04%	616.15%	-52.51%	-15.34%	0.00%	334.56%	-114.39%
Return on Net Nonoperating Assets (RNNOA)	143.34%	-11.31%	-59.91%	-89.71%	-143.17%	-21.30%	27.70%	9.92%	0.00%	-58.75%	64.96%
Return on Equity (ROE)	-76.46%	-60.42%	-97.93%	-128.46%	-189.00%	-55.68%	-28.11%	-58.48%	-164.86%	-135.71%	-101.52%
Cash Return on Invested Capital (CROIC)	-183.43%	-224.47%	-36.60%	-35.71%	-35.91%	-73.60%	-81.04%	20.80%	-131.91%	10.48%	-148.75%
Operating Return on Assets (OROA)	-70.21%	-30.87%	-32.59%	-35.98%	-42.86%	-22.45%	-17.34%	-24.11%	0.00%	-44.71%	-71.66%
Return on Assets (ROA)	-69.78%	-33.25%	-36.84%	-40.73%	-47.77%	-26.36%	-19.25%	-40.84%	0.00%	-71.22%	-70.79%
Return on Common Equity (ROCE)	-76.46%	-36.26%	-56.01%	-128.46%	-189.08%	-55.70%	-28.11%	-58.48%	-164.86%	-135.71%	-101.52%
Return on Equity Simple (ROE_SIMPLE)	-58.99%	-107.25%	-181.05%	-99.64%	-714.45%	-29.04%	-21.38%	-79.24%	-422.66%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.67	-6.93	-9.99	-9.96	-11	-9.80	-22	-21	-21	-12	-13
NOPAT Margin	-252.09%	-730.50%	-2,535.99%	-2,243.00%	-547.65%	-598.42%	-918.50%	-1,103.39%	0.00%	-5,175.02%	-3,255.35%
Net Nonoperating Expense Percent (NNEP)	-29.94%	-105.53%	62.73%	46.72%	44.21%	-650.53%	-3.29%	-53.06%	-220.78%	-411.52%	-52.09%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	-51.24%	-82.89%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	42.92%	61.66%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	271.31%	810.65%	2,677.92%	2,406.53%	611.10%	693.83%	929.19%	1,154.67%	0.00%	5,188.44%	2,672.50%
R&D to Revenue	188.82%	332.91%	1,044.92%	897.75%	271.26%	218.13%	421.30%	521.60%	0.00%	2,304.44%	2,078.00%
Operating Expenses to Revenue	460.13%	1,143.57%	3,722.84%	3,304.28%	882.36%	911.97%	1,350.49%	1,676.27%	0.00%	7,492.89%	4,750.50%
Earnings before Interest and Taxes (EBIT)	-6.67	-9.89	-14	-14	-16	-14	-21	-30	-29	-16	-19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.30	-8.95	-13	-13	-14	-12	-20	-25	-28	-14	-17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.49	6.46	3.86	0.65	5.66	4.64	3.03	0.91	0.49	0.85	0.85
Price to Tangible Book Value (P/TBV)	8.22	8.18	4.85	0.72	12.81	4.74	3.06	0.98	0.76	1.14	1.57
Price to Revenue (P/Rev)	39.39	67.68	87.31	23.50	6.91	160.41	138.74	30.57	0.00	80.87	31.51
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	36.51	3.05	1.98	0.77	1.50	7.04	6.01	2.75	0.64	0.63	0.68
Enterprise Value to Revenue (EV/Rev)	34.26	85.11	130.91	44.09	17.05	146.67	111.48	24.54	0.00	23.94	12.13
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.31	0.00	3.40	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	1.06	2.83	1.55	10.13	0.58	0.30	0.35	0.89	0.07	0.06
Long-Term Debt to Equity	0.00	1.05	2.81	1.54	10.04	0.57	0.29	0.00	0.04	0.04	0.00
Financial Leverage	-0.76	-0.20	0.59	1.05	1.59	-0.03	-0.53	-0.65	-0.51	-0.18	-0.57
Leverage Ratio	1.10	1.82	2.66	3.15	3.96	2.11	1.46	1.43	1.78	1.91	1.43
Compound Leverage Factor	1.09	1.96	3.01	3.57	4.41	2.48	1.62	1.42	1.78	1.88	1.42
Debt to Total Capital	0.00%	51.41%	73.92%	60.81%	91.01%	36.55%	22.96%	25.88%	47.09%	6.17%	5.28%
Short-Term Debt to Total Capital	0.00%	0.34%	0.54%	0.48%	0.78%	0.29%	0.43%	25.88%	45.05%	2.28%	5.28%
Long-Term Debt to Total Capital	0.00%	51.06%	73.38%	60.33%	90.23%	36.26%	22.53%	0.00%	2.04%	3.88%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	28.51%	0.00%	0.00%	-0.02%	-0.01%	-0.01%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	20.08%	26.08%	39.20%	9.01%	63.46%	77.05%	74.12%	52.91%	93.84%	94.72%
Debt to EBITDA	0.00	-2.84	-2.01	-2.00	-1.77	-2.77	-1.62	-0.87	-0.48	-0.10	-0.05
Net Debt to EBITDA	0.00	-0.27	-1.36	-0.73	-1.46	1.91	3.24	0.45	-0.23	0.90	0.44
Long-Term Debt to EBITDA	0.00	-2.82	-1.99	-1.99	-1.76	-2.75	-1.59	0.00	-0.02	-0.06	0.00
Debt to NOPAT	0.00	-3.67	-2.53	-2.52	-2.25	-3.33	-1.49	-1.07	-0.67	-0.12	-0.06
Net Debt to NOPAT	0.00	-0.35	-1.72	-0.92	-1.85	2.30	2.97	0.55	-0.31	1.10	0.60
Long-Term Debt to NOPAT	0.00	-3.65	-2.51	-2.50	-2.23	-3.30	-1.46	0.00	-0.03	-0.08	0.00
Altman Z-Score	28.52	-0.28	-3.12	-3.32	-6.13	2.21	3.83	-2.98	-11.87	-15.11	-21.59
Noncontrolling Interest Sharing Ratio	0.00%	39.99%	42.80%	0.00%	-0.04%	-0.03%	-0.02%	-0.01%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.01	10.43	4.26	8.00	1.39	11.79	15.74	1.48	1.19	4.08	1.59
Quick Ratio	7.87	10.31	4.10	7.87	1.31	10.54	14.66	1.13	0.20	3.89	1.42
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-3.89	-32	-9.62	-9.18	-8.66	-21	-32	6.32	-25	1.59	-12
Operating Cash Flow to CapEx	-36,346.15%	-11,870.59%	-994.94%	-1,443.25%	-1,519.02%	-1,237.94%	-611.06%	-511.32%	-969.92%	-19,738.30%	-95,650.00%
Free Cash Flow to Firm to Interest Expense	0.00	-39.22	-4.99	-4.79	-4.56	-8.51	-12.89	0.00	-306.58	9.22	-54.88
Operating Cash Flow to Interest Expense	0.00	-10.00	-6.82	-7.04	-7.36	-5.41	-12.25	0.00	-366.70	-107.87	-72.19
Operating Cash Flow Less CapEx to Interest Expense	0.00	-10.09	-7.51	-7.53	-7.84	-5.85	-14.26	0.00	-404.51	-108.42	-72.26
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.20	0.03	0.01	0.01	0.05	0.03	0.02	0.02	0.00	0.01	0.02
Accounts Receivable Turnover	5.70	1.80	1.01	3.55	23.47	19.05	9.47	2.64	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	3.54	0.00	0.00	0.00	0.00
Fixed Asset Turnover	194.84	0.07	0.02	0.02	0.08	0.12	0.39	0.38	0.00	0.06	0.12
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.51	0.73	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	64.09	202.33	361.76	102.76	15.56	19.16	38.56	138.13	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	102.98	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	716.50	500.94	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	64.09	202.33	361.76	102.76	15.56	-697.34	-359.39	138.13	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1.74	26	26	25	23	34	44	17	22	8.52	7.13
Invested Capital Turnover	0.87	0.07	0.02	0.02	0.08	0.06	0.06	0.06	0.00	0.01	0.05
Increase / (Decrease) in Invested Capital	-0.77	25	-0.37	-0.78	-2.39	11	9.85	-27	4.91	-13	-1.39
Enterprise Value (EV)	63	81	52	20	34	240	264	46	14	5.39	4.85
Market Capitalization	73	64	34	10	14	263	329	58	7.55	18	13
Book Value per Share	$0.15	$0.11	$0.10	$0.14	$0.13	$0.48	$0.50	$0.29	$1.24	$2.47	$0.90
Tangible Book Value per Share	$0.12	$0.09	$0.08	$0.13	$0.06	$0.47	$0.49	$0.27	$0.81	$1.85	$0.49
Total Capital	11	49	34	41	27	89	141	86	29	23	16
Total Debt	0.00	25	25	25	25	33	32	22	14	1.40	0.83
Total Long-Term Debt	0.00	25	25	25	25	32	32	0.00	0.59	0.88	0.00
Net Debt	-9.49	2.42	17	9.15	20	-23	-65	-11	6.36	-13	-7.75
Capital Expenditures (CapEx)	0.01	0.07	1.32	0.93	0.92	1.08	4.92	7.33	3.14	0.09	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.64	-1.23	-1.35	-1.49	-2.86	1.66	1.58	3.27	9.92	-1.86	-4.14
Debt-free Net Working Capital (DFNWC)	8.86	22	6.74	14	1.56	57	99	37	17	12	4.45
Net Working Capital (NWC)	8.86	22	6.56	14	1.35	57	98	15	4.15	12	3.62
Net Nonoperating Expense (NNE)	1.96	3.73	6.15	6.15	6.55	6.64	1.44	30	44	13	5.36
Net Nonoperating Obligations (NNO)	-9.49	2.42	17	9.15	20	-23	-65	-47	6.36	-13	-7.75
Total Depreciation and Amortization (D&A)	0.36	0.94	1.68	1.71	1.75	2.24	0.98	4.21	1.11	1.37	1.13
Debt-free, Cash-free Net Working Capital to Revenue	-34.36%	-129.64%	-341.62%	-334.91%	-141.63%	101.40%	66.55%	173.78%	0.00%	-826.22%	-1,034.25%
Debt-free Net Working Capital to Revenue	478.55%	2,298.00%	1,711.17%	3,253.83%	77.45%	3,466.00%	4,156.56%	1,953.03%	0.00%	5,489.33%	1,111.25%
Net Working Capital to Revenue	478.55%	2,280.06%	1,664.72%	3,209.46%	66.90%	3,450.06%	4,131.25%	776.75%	0.00%	5,258.67%	903.75%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($450.00)	($600.00)	($800.00)	($770.00)	($470.00)	($305.00)	($60.00)	($115.60)	($106.20)	$0.00	($1.75)
Adjusted Weighted Average Basic Shares Outstanding	14.30K	16.20K	18.56K	36.67K	48.31K	125.59K	435.75K	436.05K	612.25K	0.00	10.50M
Adjusted Diluted Earnings per Share	($450.00)	($600.00)	($800.00)	($770.00)	($470.00)	($305.00)	($60.00)	($115.60)	($106.20)	$0.00	($1.75)
Adjusted Weighted Average Diluted Shares Outstanding	14.30K	16.20K	18.56K	36.67K	48.31K	125.59K	435.75K	436.05K	612.25K	0.00	10.50M
Adjusted Basic & Diluted Earnings per Share	($450.00)	($600.00)	($800.00)	($770.00)	($470.00)	($305.00)	($60.00)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	14.30K	16.20K	17.82K	21.26K	37.85K	125.59K	391.24K	0.00	1.38M	0.00	19.65M
Normalized Net Operating Profit after Tax (NOPAT)	-4.67	-6.93	-9.99	-9.96	-11	-9.80	-22	-21	-21	-12	-13
Normalized NOPAT Margin	-252.09%	-730.50%	-2,535.99%	-2,243.00%	-547.65%	-598.42%	-918.50%	-1,103.39%	0.00%	-5,175.02%	-3,255.35%
Pre Tax Income Margin	-357.91%	-1,124.16%	-4,096.19%	-3,627.93%	-872.00%	-1,003.91%	-979.04%	-1,566.51%	0.00%	-6,863.56%	-4,594.25%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-12.26	-7.40	-7.43	-8.31	-5.68	-8.52	0.00	-353.53	-90.90	-87.75
NOPAT to Interest Expense	0.00	-8.58	-5.18	-5.20	-5.82	-3.97	-8.87	0.00	-247.47	-67.70	-61.42
EBIT Less CapEx to Interest Expense	0.00	-12.34	-8.09	-7.92	-8.79	-6.12	-10.53	0.00	-391.34	-91.44	-87.82
NOPAT Less CapEx to Interest Expense	0.00	-8.67	-5.87	-5.69	-6.30	-4.41	-10.88	0.00	-285.28	-68.24	-61.50
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.10%	-0.06%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-7.29%	-0.90%	-13.20%	-20.30%	-0.10%	-0.06%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from iBio's official financial filings.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	27,586,499.00	28,100,733.00	3,484,266.00	8,623,676.00	8,637,895.00	9,149,470.00	9,874,676.00	16,519,281.00	19,654,636.00	44,974,616.00	34,543,561.00
DEI Adjusted Shares Outstanding	1,379,325.00	1,405,037.00	3,484,266.00	8,623,676.00	8,637,895.00	9,149,470.00	9,874,676.00	16,519,281.00	19,654,636.00	44,974,616.00	34,543,561.00
DEI Earnings Per Adjusted Shares Outstanding	-4.17	-5.84	-0.91	-0.90	-0.46	-0.48	-0.49	-0.31	-0.29	-0.20	-0.22
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	14.29%	0.00%	-100.00%	0.00%
EBITDA Growth	33.56%	59.20%	61.40%	39.36%	18.47%	-7.19%	-87.01%	-57.07%	-52.35%	-110.98%	-84.85%
EBIT Growth	33.17%	57.48%	58.10%	31.34%	19.54%	1.71%	-85.80%	-52.48%	-44.93%	-113.74%	-71.45%
NOPAT Growth	33.17%	57.48%	41.22%	31.34%	19.54%	1.71%	-34.56%	-52.48%	-44.93%	-113.74%	-71.45%
Net Income Growth	68.31%	75.53%	56.51%	-28.92%	30.58%	46.85%	-53.25%	33.62%	-43.39%	-106.07%	-59.02%
EPS Growth	68.31%	93.54%	92.32%	79.41%	90.42%	89.14%	42.35%	75.86%	76.09%	81.25%	87.76%
Operating Cash Flow Growth	61.75%	38.36%	5.63%	2.33%	30.43%	17.79%	15.02%	4.92%	-52.49%	-35.46%	-95.94%
Free Cash Flow Firm Growth	334.00%	-54.89%	-160.25%	229.36%	-37.12%	140.42%	309.23%	-120.77%	-122.17%	-117.10%	-103.12%
Invested Capital Growth	-51.99%	-25.54%	35.25%	-60.84%	-70.46%	-63.07%	-78.53%	-16.29%	-8.32%	-54.65%	-64.92%
Revenue Q/Q Growth	0.00%	-100.00%	0.00%	0.00%	-100.00%	0.00%	-100.00%	0.00%	-50.00%	-100.00%	0.00%
EBITDA Q/Q Growth	8.98%	11.67%	44.68%	-36.36%	-22.38%	-16.12%	3.49%	-6.87%	-18.71%	-60.80%	15.44%
EBIT Q/Q Growth	-2.78%	11.90%	41.59%	-29.82%	-20.45%	-7.62%	-10.41%	-6.54%	-14.49%	-58.71%	11.43%
NOPAT Q/Q Growth	-2.78%	11.90%	19.35%	5.98%	-20.45%	-7.62%	-10.41%	-6.54%	-14.49%	-58.71%	11.43%
Net Income Q/Q Growth	4.76%	-42.90%	61.37%	-145.21%	48.71%	-9.40%	-11.39%	-6.21%	-10.79%	-57.22%	14.04%
EPS Q/Q Growth	4.76%	7.92%	80.77%	-138.82%	77.34%	-4.35%	-2.08%	0.00%	77.55%	18.18%	33.33%
Operating Cash Flow Q/Q Growth	-7.44%	11.87%	22.35%	-32.84%	23.47%	-4.15%	19.75%	-48.63%	-22.75%	7.48%	-16.08%
Free Cash Flow Firm Q/Q Growth	400.64%	-81.10%	-352.36%	190.21%	46.12%	-27.73%	119.62%	-108.95%	-56.01%	44.27%	59.92%
Invested Capital Q/Q Growth	22.17%	-13.19%	57.74%	-76.59%	-7.85%	8.53%	-8.28%	-8.74%	0.93%	-46.32%	-29.05%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	0.00%	0.00%	100.00%	0.00%	100.00%	0.00%	100.00%	100.00%	0.00%	0.00%
EBITDA Margin	-9,390.00%	0.00%	0.00%	-1,787.43%	0.00%	-2,222.50%	0.00%	-2,456.50%	-5,832.00%	0.00%	0.00%
Operating Margin	-10,206.00%	0.00%	0.00%	-1,948.00%	0.00%	-2,209.50%	0.00%	-2,599.00%	-5,951.00%	0.00%	0.00%
EBIT Margin	-10,206.00%	0.00%	0.00%	-1,948.00%	0.00%	-2,209.50%	0.00%	-2,599.00%	-5,951.00%	0.00%	0.00%
Profit (Net Income) Margin	-11,492.00%	0.00%	0.00%	-4,444.57%	0.00%	-2,182.00%	0.00%	-2,581.50%	-5,720.00%	0.00%	0.00%
Tax Burden Percent	113.24%	182.95%	120.38%	239.62%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	99.43%	99.82%	100.34%	95.22%	97.15%	98.76%	99.63%	99.33%	96.12%	95.21%	92.41%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-8.72%	0.00%	0.00%	-20.28%	0.00%	-36.74%	0.00%	-93.04%	-276.96%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-30.12%	0.00%	0.00%	147.01%	0.00%	-66.69%	0.00%	-78.21%	-271.67%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-9.94%	0.00%	0.00%	-25.82%	0.00%	-24.50%	0.00%	44.42%	216.29%	0.00%	0.00%
Return on Equity (ROE)	-18.66%	0.00%	0.00%	-46.10%	0.00%	-61.24%	0.00%	-48.62%	-60.66%	0.00%	0.00%
Cash Return on Invested Capital (CROIC)	24.43%	-24.44%	-70.22%	10.48%	45.17%	23.13%	76.02%	-148.75%	-181.64%	-212.91%	-288.13%
Operating Return on Assets (OROA)	-8.35%	0.00%	0.00%	-12.53%	0.00%	-29.74%	0.00%	-40.05%	-67.11%	0.00%	0.00%
Return on Assets (ROA)	-9.40%	0.00%	0.00%	-28.60%	0.00%	-29.37%	0.00%	-39.78%	-64.51%	0.00%	0.00%
Return on Common Equity (ROCE)	-18.66%	0.00%	0.00%	-46.10%	0.00%	-61.24%	0.00%	-48.62%	-60.66%	0.00%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-398.41%	-296.66%	-93.16%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.57	-3.15	-2.54	-2.39	-2.87	-3.09	-3.42	-3.64	-4.17	-6.61	-5.86
NOPAT Margin	-7,144.20%	0.00%	0.00%	-1,363.60%	0.00%	-1,546.65%	0.00%	-1,819.30%	-4,165.70%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	21.39%	38.94%	6.03%	-167.29%	64.64%	29.96%	36.41%	-14.83%	-5.29%	-8.20%	-4.78%
Return On Investment Capital (ROIC_SIMPLE)	-	-12.60%	-6.24%	-10.50%	-15.22%	-19.92%	-26.74%	-23.16%	-7.34%	-11.69%	-7.55%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	7,094.00%	0.00%	0.00%	1,396.57%	0.00%	1,371.00%	0.00%	1,087.00%	2,501.00%	0.00%	0.00%
R&D to Revenue	3,212.00%	0.00%	0.00%	651.43%	0.00%	938.50%	0.00%	1,612.00%	3,550.00%	0.00%	0.00%
Operating Expenses to Revenue	10,306.00%	0.00%	0.00%	2,048.00%	0.00%	2,309.50%	0.00%	2,699.00%	6,051.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-5.10	-4.50	-2.63	-3.41	-4.11	-4.42	-4.88	-5.20	-5.95	-9.45	-8.37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.70	-4.15	-2.29	-3.13	-3.83	-4.45	-4.29	-4.91	-5.83	-9.38	-7.93
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.63	0.21	0.57	0.85	1.08	1.61	3.49	0.85	0.29	0.77	0.85
Price to Tangible Book Value (P/TBV)	1.07	0.50	0.73	1.14	1.55	2.88	7.52	1.57	0.33	0.83	0.87
Price to Revenue (P/Rev)	167.45	38.50	282.92	80.87	109.58	59.78	105.86	31.51	32.54	144.67	218.78
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.74	0.60	0.65	0.63	1.18	2.00	4.63	0.68	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	395.79	277.04	474.48	23.94	52.97	45.43	96.34	12.13	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	1.98	0.00	0.00	3.40	1.19	4.67	2.15	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.21	1.71	0.64	0.07	0.06	0.12	0.12	0.06	0.01	0.00	0.00
Long-Term Debt to Equity	0.25	0.34	0.12	0.04	0.04	0.05	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.33	0.93	0.50	-0.18	0.11	0.37	0.22	-0.57	-0.80	-0.82	-0.88
Leverage Ratio	1.99	3.06	2.24	1.91	2.01	2.41	1.91	1.43	1.20	1.22	1.18
Compound Leverage Factor	1.97	3.06	2.25	1.81	1.95	2.38	1.90	1.42	1.16	1.16	1.09
Debt to Total Capital	54.66%	63.17%	38.85%	6.17%	5.99%	10.53%	10.88%	5.28%	1.27%	0.00%	0.00%
Short-Term Debt to Total Capital	43.33%	50.68%	31.64%	2.28%	2.17%	6.39%	10.88%	5.28%	1.27%	0.00%	0.00%
Long-Term Debt to Total Capital	11.33%	12.48%	7.21%	3.88%	3.82%	4.14%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	45.34%	36.83%	61.15%	93.84%	94.01%	89.47%	89.12%	94.72%	98.73%	100.00%	100.00%
Debt to EBITDA	-0.62	-0.79	-0.91	-0.10	-0.08	-0.11	-0.09	-0.05	-0.04	0.00	0.00
Net Debt to EBITDA	-0.44	-0.60	-0.55	0.90	0.69	0.37	0.23	0.44	2.51	0.00	0.00
Long-Term Debt to EBITDA	-0.13	-0.16	-0.17	-0.06	-0.05	-0.04	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.85	-1.09	-1.24	-0.12	-0.10	-0.15	-0.12	-0.06	-0.05	0.00	0.00
Net Debt to NOPAT	-0.61	-0.82	-0.75	1.10	0.91	0.49	0.30	0.60	3.41	0.00	0.00
Long-Term Debt to NOPAT	-0.18	-0.21	-0.23	-0.08	-0.07	-0.06	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-11.12	-12.92	-8.03	-13.71	-16.59	-19.52	-21.67	-19.69	-5.63	-3.81	-0.37
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.11	0.91	1.69	4.08	3.37	1.76	1.12	1.59	8.39	9.04	11.88
Quick Ratio	0.07	0.13	0.25	3.89	3.18	1.49	0.92	1.42	8.21	8.93	11.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	25	4.76	-12	11	16	11	25	-2.25	-3.51	-1.96	-0.78
Operating Cash Flow to CapEx	0.00%	-9,412.00%	0.00%	-3,370.83%	0.00%	-386,900.00%	-22,178.57%	-461,500.00%	-17,703.13%	-1,015.70%	-55,309.09%
Free Cash Flow to Firm to Interest Expense	969.15	140.08	-231.14	180.71	277.96	200.89	465.70	-51.17	-97.58	-47.74	-35.66
Operating Cash Flow to Interest Expense	-205.38	-138.41	-70.27	-80.90	-65.18	-67.88	-57.50	-104.89	-157.36	-127.83	-276.55
Operating Cash Flow Less CapEx to Interest Expense	-203.46	-139.88	-70.27	-83.30	-65.18	-67.89	-57.76	-104.91	-158.25	-140.41	-277.05
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.01	0.01	0.01	0.01	0.02	0.01	0.01	0.01
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.01	0.01	0.01	0.06	0.05	0.10	0.11	0.12	0.15	0.09	0.09
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	27	23	36	8.52	7.85	8.52	7.81	7.13	7.19	3.86	2.74
Invested Capital Turnover	0.00	0.00	0.00	0.01	0.01	0.02	0.02	0.05	0.07	0.05	0.06
Increase / (Decrease) in Invested Capital	-29	-7.91	9.48	-13	-19	-15	-29	-1.39	-0.65	-4.65	-5.07
Enterprise Value (EV)	20	14	24	5.39	9.27	17	36	4.85	-33	-9.30	-9.16
Market Capitalization	8.37	1.92	14	18	19	22	40	13	16	43	66
Book Value per Share	$0.48	$0.33	$7.14	$2.47	$2.06	$1.52	$1.15	$0.90	$2.85	$2.52	$2.24
Tangible Book Value per Share	$0.28	$0.14	$5.59	$1.85	$1.43	$0.85	$0.53	$0.49	$2.50	$2.32	$2.19
Total Capital	29	25	41	23	19	16	13	16	57	57	78
Total Debt	16	16	16	1.40	1.13	1.64	1.39	0.83	0.72	0.00	0.00
Total Long-Term Debt	3.30	3.12	2.93	0.88	0.72	0.64	0.00	0.00	0.00	0.00	0.00
Net Debt	11	12	9.58	-13	-9.91	-5.38	-3.57	-7.75	-49	-53	-75
Capital Expenditures (CapEx)	-0.05	0.05	0.00	0.14	0.00	0.00	0.01	0.00	0.03	0.52	0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	10	6.96	21	-1.86	-2.39	-2.45	-2.91	-4.14	-4.12	-5.23	-4.05
Debt-free Net Working Capital (DFNWC)	15	11	28	12	8.65	4.57	2.05	4.45	45	47	71
Net Working Capital (NWC)	2.31	-1.85	15	12	8.24	3.58	0.66	3.62	45	47	71
Net Nonoperating Expense (NNE)	2.17	5.06	0.63	5.39	1.11	1.27	1.45	1.52	1.55	2.38	1.87
Net Nonoperating Obligations (NNO)	13	14	12	-13	-9.91	-5.38	-3.57	-7.75	-49	-53	-75
Total Depreciation and Amortization (D&A)	0.41	0.35	0.33	0.28	0.28	-0.03	0.59	0.29	0.12	0.07	0.44
Debt-free, Cash-free Net Working Capital to Revenue	20,862.00%	13,912.00%	42,720.00%	-826.22%	-1,367.43%	-652.27%	-775.20%	-1,034.25%	-824.20%	-1,743.67%	-1,350.00%
Debt-free Net Working Capital to Revenue	29,878.00%	21,602.00%	55,152.00%	5,489.33%	4,940.00%	1,218.40%	547.20%	1,111.25%	9,089.20%	15,822.33%	23,582.33%
Net Working Capital to Revenue	4,628.00%	-3,708.00%	29,426.00%	5,258.67%	4,706.29%	953.60%	176.80%	903.75%	8,944.80%	15,822.33%	23,582.33%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.80)	($4.42)	($0.85)	($2.03)	($0.46)	($0.48)	($0.49)	($0.49)	($0.11)	($0.09)	($0.06)
Adjusted Weighted Average Basic Shares Outstanding	1.20M	1.86M	3.71M	3.83M	8.63M	9.13M	9.86M	10.50M	52.98M	99.13M	119.60M
Adjusted Diluted Earnings per Share	($4.80)	($4.42)	($0.85)	($2.03)	($0.46)	($0.48)	($0.49)	($0.49)	($0.11)	($0.09)	($0.06)
Adjusted Weighted Average Diluted Shares Outstanding	1.20M	1.86M	3.71M	3.83M	8.63M	9.13M	9.86M	10.50M	52.98M	99.13M	119.60M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($2.03)	$0.00	$0.00	$0.00	($0.49)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.41M	3.48M	8.62M	8.64M	9.15M	9.87M	16.52M	19.65M	22.49M	34.54M	49.68M
Normalized Net Operating Profit after Tax (NOPAT)	-3.57	-3.15	-2.54	-2.39	-2.87	-3.09	-3.42	-3.64	-4.17	-6.61	-5.86
Normalized NOPAT Margin	-7,144.20%	0.00%	0.00%	-1,363.60%	0.00%	-1,546.65%	0.00%	-1,819.30%	-4,165.70%	0.00%	0.00%
Pre Tax Income Margin	-10,148.00%	0.00%	0.00%	-1,854.86%	0.00%	-2,182.00%	0.00%	-2,581.50%	-5,720.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-196.27	-132.24	-50.50	-56.82	-72.04	-77.53	-90.35	-118.14	-165.31	-230.37	-380.23
NOPAT to Interest Expense	-137.39	-92.56	-48.81	-39.77	-50.42	-54.27	-63.25	-82.70	-115.71	-161.26	-266.16
EBIT Less CapEx to Interest Expense	-194.35	-133.71	-50.50	-59.22	-72.04	-77.54	-90.61	-118.16	-166.19	-242.95	-380.73
NOPAT Less CapEx to Interest Expense	-135.47	-94.04	-48.81	-42.17	-50.42	-54.29	-63.51	-82.72	-116.60	-173.84	-266.66
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

iBio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, iBio's financial year ends in June. Their financial year 2025 ended on June 30, 2025.

iBio's net income appears to be on an upward trend, with a most recent value of -$18.38 million in 2025, rising from -$6.63 million in 2015. The previous period was -$24.91 million in 2024. View iBio's forecast to see where analysts expect iBio to go next.

iBio's total operating income in 2025 was -$18.60 million, based on the following breakdown:

Total Gross Profit: $400 thousand
Total Operating Expenses: $19.00 million

Over the last 10 years, iBio's total revenue changed from $1.85 million in 2015 to $400 thousand in 2025, a change of -78.4%.

iBio's total liabilities were at $8.31 million at the end of 2025, a 12.1% increase from 2024, and a 557.6% increase since 2015.

In the past 10 years, iBio's cash and equivalents has ranged from $4.30 million in 2023 to $77.40 million in 2021, and is currently $8.58 million as of their latest financial filing in 2025.

Over the last 10 years, iBio's book value per share changed from 0.15 in 2015 to 0.90 in 2025, a change of 515.7%.

Related Companies

Financial statements for NASDAQ:IBIO last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iBio (IBIO) Financials

Financials Breakdown Chart

iBio Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iBio (IBIO) Financials

Annual Income Statements for iBio

Quarterly Income Statements for iBio

Annual Cash Flow Statements for iBio

Quarterly Cash Flow Statements for iBio

Annual Balance Sheets for iBio

Quarterly Balance Sheets for iBio

Annual Metrics And Ratios for iBio

Quarterly Metrics And Ratios for iBio

Financials Breakdown Chart

iBio Financials - Frequently Asked Questions

When does iBio's fiscal year end?

How has iBio's net income changed over the last 10 years?

What is iBio's operating income?

How has iBio's revenue changed over the last 10 years?

How much debt does iBio have?

How much cash does iBio have?

How has iBio's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools